Research
Neural
Tirzepatide is associated with a lower risk of dementia versus SGLT2 inhibitors (HR 0.66, 95% CI 0.47-0.93, p = 0.02).
Tirzepatide may be a preferable treatment option for reducing dementia risk in type 2 diabetes patients compared to SGLT2 inhibitors.
StrongSupportsmedium confidence
Tirzepatide was associated with a lower risk of dementia versus SGLT2-i (HR 0.66, 95% CI 0.47-0.93, p = 0.02).
Why this rating
Based on the large cohort study design.
Source
Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study
Alhena Younis et al. · Diabetes Research and Clinical Practice · 2026
cohort · n=14462
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →